. 2009 Sep 26;101(1):22–28. doi: 10.1111/j.1349-7006.2009.01373.x

Table 3.

Randomized trials of first‐line chemotherapy in patients with poor‐risk metastatic disease

Source	No. patients	Risk system (%)	Regimens (%)	PFS	OS	Conclusion
Nichols et al. ⁽ ³⁴ ⁾	286	Indiana⁽ ¹¹ ⁾	BEP × 4	60†	71	VIP not superior and more toxic
Nichols et al. ⁽ ³⁴ ⁾	286	Indiana⁽ ¹¹ ⁾	VIP × 4	64	74	VIP not superior and more toxic
Kaye et al. ⁽ ³⁵ ⁾	271	MRC/EORTC⁽ ¹² ⁾	BEP × 4/EP × 2	60†	76	BOP/VIP‐B not superior and more toxic
Kaye et al. ⁽ ³⁵ ⁾	271	MRC/EORTC⁽ ¹² ⁾	BOP × 3 + VIP‐B × 2	53	69	BOP/VIP‐B not superior and more toxic
Culine et al. ⁽ ³⁷ ⁾	185	IGR⁽ ¹³ ⁾	BEP × 4	47‡	69	CISCA/VB not superior and more toxic
Culine et al. ⁽ ³⁷ ⁾	185	IGR⁽ ¹³ ⁾	CISCA/VB × 4–6	37	59	CISCA/VB not superior and more toxic
Droz et al. ⁽ ³⁸ ⁾	114	IGR⁽ ¹³ ⁾	BEP₂₀₀V × 4	54	75	HD‐PEC not superior and more toxic
Droz et al. ⁽ ³⁸ ⁾	114	IGR⁽ ¹³ ⁾	BEP₂₀₀V × 2 + HD‐PEC × 2	47	61	HD‐PEC not superior and more toxic
Motzer et al. ⁽ ³⁹ ⁾	174	IGCCCG⁽ ¹⁴ ⁾	BEP × 4	46§	69	HD‐CEC not superior and more toxic
Motzer et al. ⁽ ³⁹ ⁾	174	IGCCCG⁽ ¹⁴ ⁾	BEP × 2 + HD‐CEC × 2	48	67	HD‐CEC not superior and more toxic

†Failure‐free survival; ‡event‐free survival; §1‐year durable response rate. BEP₂₀₀V, bleomycin, etoposide, vinblastine, and double‐dose cisplatin; BOP/VIP‐B, bleomycin, vincristine and cisplatin/VIP combined bleomycin; CEC, carboplatin, etoposide, and cyclophosphamide; CISCA/VB, cyclophosphamide, doxorubicin, cisplatin/vinblastine, bleomycin; HD, high dose; OS, overall survival; PEC, etoposide, cyclophosphamide, and double‐dose cisplatin; PFS, progression‐free survival.